BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes

Raffaele Rocco, Raffaele Antonelli Incalzi, Giorgio Pennazza, Marco Santonico, Claudio Pedone, Isaura Rossi Bartoli, Chiara Vernile, Giuseppe Mangiameli, Antonello La Rocca, Giuseppe De Luca, Gaetano Rocco, Pierfilippo Crucitti

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

OBJECTIVES: Breath composition may be suggestive of different conditions. E-nose technology has been used to profile volatile organic compounds (VOCs) pattern in the breath of patients compared with that of healthy individuals. BIOsensor-based multisensorial system for mimicking NOse, Tongue and Eyes (BIONOTE) technology differs from Cyranose® based on a set of separate transduction features. On the basis of our previously published experience, we investigated the discriminating ability of BIONOTE in a high-risk population enrolled in a lung cancer screening programme. METHODS: One hundred individuals were selected for BIONOTE based on the attribution to the high-risk category (i.e. age, smoking status, chronic obstructive pulmonary disease status) of the University Campus Bio-Medico lung screening programme. We used a measure chain consisting of (i) a device named Pneumopipe (EU patent: EP2641537 (A1):2013-09-25) able to catch exhaled breath by an individual normally breathing into it and collect the exhalate onto an adsorbing cartridge; (ii) an apparatus for thermal desorption of the cartridge into the sensors chamber and (iii) a gas sensor array which is part of a sensorial platform named BIONOTE for the VOCs mixture analysis. Partial least square (PLS) has been used to build up the model, with Leave-One-Out cross-validation criterion. Each breath fingerprint analysis costs €10. RESULTS: The overall sensitivity and specificity were 86 and 95%, respectively, delineating a substantial difference between patients and healthy individuals. CONCLUSIONS: Our preliminary data show that BIONOTE technology may be used to reduce false-positive rates resulting from lung cancer screening with low-dose computed tomography in a cost-effective fashion. The model will be tested on a larger number of patients to confirm the reliability of these results.

Original languageEnglish
Article numberezv328
Pages (from-to)1112-1117
Number of pages6
JournalEuropean Journal of Cardio-thoracic Surgery
Volume49
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Electronic Nose
Early Detection of Cancer
Volatile Organic Compounds
Lung Neoplasms
Technology
Nose
Costs and Cost Analysis
Aptitude
Dermatoglyphics
Biosensing Techniques
Least-Squares Analysis
Tongue
Reproducibility of Results
Chronic Obstructive Pulmonary Disease
Respiration
Hot Temperature
Gases
Smoking
Tomography
Sensitivity and Specificity

Keywords

  • E-nose
  • Lung cancer
  • Screening

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Rocco, R., Incalzi, R. A., Pennazza, G., Santonico, M., Pedone, C., Bartoli, I. R., ... Crucitti, P. (2016). BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes. European Journal of Cardio-thoracic Surgery, 49(4), 1112-1117. [ezv328]. https://doi.org/10.1093/ejcts/ezv328

BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes. / Rocco, Raffaele; Incalzi, Raffaele Antonelli; Pennazza, Giorgio; Santonico, Marco; Pedone, Claudio; Bartoli, Isaura Rossi; Vernile, Chiara; Mangiameli, Giuseppe; Rocca, Antonello La; De Luca, Giuseppe; Rocco, Gaetano; Crucitti, Pierfilippo.

In: European Journal of Cardio-thoracic Surgery, Vol. 49, No. 4, ezv328, 01.04.2016, p. 1112-1117.

Research output: Contribution to journalArticle

Rocco, R, Incalzi, RA, Pennazza, G, Santonico, M, Pedone, C, Bartoli, IR, Vernile, C, Mangiameli, G, Rocca, AL, De Luca, G, Rocco, G & Crucitti, P 2016, 'BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes', European Journal of Cardio-thoracic Surgery, vol. 49, no. 4, ezv328, pp. 1112-1117. https://doi.org/10.1093/ejcts/ezv328
Rocco R, Incalzi RA, Pennazza G, Santonico M, Pedone C, Bartoli IR et al. BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes. European Journal of Cardio-thoracic Surgery. 2016 Apr 1;49(4):1112-1117. ezv328. https://doi.org/10.1093/ejcts/ezv328
Rocco, Raffaele ; Incalzi, Raffaele Antonelli ; Pennazza, Giorgio ; Santonico, Marco ; Pedone, Claudio ; Bartoli, Isaura Rossi ; Vernile, Chiara ; Mangiameli, Giuseppe ; Rocca, Antonello La ; De Luca, Giuseppe ; Rocco, Gaetano ; Crucitti, Pierfilippo. / BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes. In: European Journal of Cardio-thoracic Surgery. 2016 ; Vol. 49, No. 4. pp. 1112-1117.
@article{ed3dd89de4c04d3ebd310705d740e2c2,
title = "BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes",
abstract = "OBJECTIVES: Breath composition may be suggestive of different conditions. E-nose technology has been used to profile volatile organic compounds (VOCs) pattern in the breath of patients compared with that of healthy individuals. BIOsensor-based multisensorial system for mimicking NOse, Tongue and Eyes (BIONOTE) technology differs from Cyranose{\circledR} based on a set of separate transduction features. On the basis of our previously published experience, we investigated the discriminating ability of BIONOTE in a high-risk population enrolled in a lung cancer screening programme. METHODS: One hundred individuals were selected for BIONOTE based on the attribution to the high-risk category (i.e. age, smoking status, chronic obstructive pulmonary disease status) of the University Campus Bio-Medico lung screening programme. We used a measure chain consisting of (i) a device named Pneumopipe (EU patent: EP2641537 (A1):2013-09-25) able to catch exhaled breath by an individual normally breathing into it and collect the exhalate onto an adsorbing cartridge; (ii) an apparatus for thermal desorption of the cartridge into the sensors chamber and (iii) a gas sensor array which is part of a sensorial platform named BIONOTE for the VOCs mixture analysis. Partial least square (PLS) has been used to build up the model, with Leave-One-Out cross-validation criterion. Each breath fingerprint analysis costs €10. RESULTS: The overall sensitivity and specificity were 86 and 95{\%}, respectively, delineating a substantial difference between patients and healthy individuals. CONCLUSIONS: Our preliminary data show that BIONOTE technology may be used to reduce false-positive rates resulting from lung cancer screening with low-dose computed tomography in a cost-effective fashion. The model will be tested on a larger number of patients to confirm the reliability of these results.",
keywords = "E-nose, Lung cancer, Screening",
author = "Raffaele Rocco and Incalzi, {Raffaele Antonelli} and Giorgio Pennazza and Marco Santonico and Claudio Pedone and Bartoli, {Isaura Rossi} and Chiara Vernile and Giuseppe Mangiameli and Rocca, {Antonello La} and {De Luca}, Giuseppe and Gaetano Rocco and Pierfilippo Crucitti",
year = "2016",
month = "4",
day = "1",
doi = "10.1093/ejcts/ezv328",
language = "English",
volume = "49",
pages = "1112--1117",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "European Association for Cardio-Thoracic Surgery",
number = "4",

}

TY - JOUR

T1 - BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes

AU - Rocco, Raffaele

AU - Incalzi, Raffaele Antonelli

AU - Pennazza, Giorgio

AU - Santonico, Marco

AU - Pedone, Claudio

AU - Bartoli, Isaura Rossi

AU - Vernile, Chiara

AU - Mangiameli, Giuseppe

AU - Rocca, Antonello La

AU - De Luca, Giuseppe

AU - Rocco, Gaetano

AU - Crucitti, Pierfilippo

PY - 2016/4/1

Y1 - 2016/4/1

N2 - OBJECTIVES: Breath composition may be suggestive of different conditions. E-nose technology has been used to profile volatile organic compounds (VOCs) pattern in the breath of patients compared with that of healthy individuals. BIOsensor-based multisensorial system for mimicking NOse, Tongue and Eyes (BIONOTE) technology differs from Cyranose® based on a set of separate transduction features. On the basis of our previously published experience, we investigated the discriminating ability of BIONOTE in a high-risk population enrolled in a lung cancer screening programme. METHODS: One hundred individuals were selected for BIONOTE based on the attribution to the high-risk category (i.e. age, smoking status, chronic obstructive pulmonary disease status) of the University Campus Bio-Medico lung screening programme. We used a measure chain consisting of (i) a device named Pneumopipe (EU patent: EP2641537 (A1):2013-09-25) able to catch exhaled breath by an individual normally breathing into it and collect the exhalate onto an adsorbing cartridge; (ii) an apparatus for thermal desorption of the cartridge into the sensors chamber and (iii) a gas sensor array which is part of a sensorial platform named BIONOTE for the VOCs mixture analysis. Partial least square (PLS) has been used to build up the model, with Leave-One-Out cross-validation criterion. Each breath fingerprint analysis costs €10. RESULTS: The overall sensitivity and specificity were 86 and 95%, respectively, delineating a substantial difference between patients and healthy individuals. CONCLUSIONS: Our preliminary data show that BIONOTE technology may be used to reduce false-positive rates resulting from lung cancer screening with low-dose computed tomography in a cost-effective fashion. The model will be tested on a larger number of patients to confirm the reliability of these results.

AB - OBJECTIVES: Breath composition may be suggestive of different conditions. E-nose technology has been used to profile volatile organic compounds (VOCs) pattern in the breath of patients compared with that of healthy individuals. BIOsensor-based multisensorial system for mimicking NOse, Tongue and Eyes (BIONOTE) technology differs from Cyranose® based on a set of separate transduction features. On the basis of our previously published experience, we investigated the discriminating ability of BIONOTE in a high-risk population enrolled in a lung cancer screening programme. METHODS: One hundred individuals were selected for BIONOTE based on the attribution to the high-risk category (i.e. age, smoking status, chronic obstructive pulmonary disease status) of the University Campus Bio-Medico lung screening programme. We used a measure chain consisting of (i) a device named Pneumopipe (EU patent: EP2641537 (A1):2013-09-25) able to catch exhaled breath by an individual normally breathing into it and collect the exhalate onto an adsorbing cartridge; (ii) an apparatus for thermal desorption of the cartridge into the sensors chamber and (iii) a gas sensor array which is part of a sensorial platform named BIONOTE for the VOCs mixture analysis. Partial least square (PLS) has been used to build up the model, with Leave-One-Out cross-validation criterion. Each breath fingerprint analysis costs €10. RESULTS: The overall sensitivity and specificity were 86 and 95%, respectively, delineating a substantial difference between patients and healthy individuals. CONCLUSIONS: Our preliminary data show that BIONOTE technology may be used to reduce false-positive rates resulting from lung cancer screening with low-dose computed tomography in a cost-effective fashion. The model will be tested on a larger number of patients to confirm the reliability of these results.

KW - E-nose

KW - Lung cancer

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84963772879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963772879&partnerID=8YFLogxK

U2 - 10.1093/ejcts/ezv328

DO - 10.1093/ejcts/ezv328

M3 - Article

VL - 49

SP - 1112

EP - 1117

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 4

M1 - ezv328

ER -